+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Neuromodulation Devices Global Market- Forecast To 2029

  • PDF Icon

    Report

  • 490 Pages
  • March 2023
  • Region: Global
  • IQ4I Research & Consultancy Pvt. Ltd
  • ID: 4844546
Description Jump to:

Neuromodulation is the alteration of nerve activity through the delivery of an electric and magnetic stimulus. Applications for neuromodulation include therapies for a wide range of disorders, as well as a tool for medical and neuroscientific research. It is used as a treatment for unmanageable chronic pain, movement disorders, neurological diseases, gastroenterology, respiratory related diseases and others. The treatment delivered by neuromodulation devices brings about life-changing transformation in patients who fail to get better by traditional approaches. This therapy is based on the natural process of stimulation of nerve cell activity and release of neurotransmitters that regulate nerve activity. Neuromodulation is gaining popularity because these devices have been very successful in the treatment of conditions for which medicines have failed completely or may have unpleasant side effects.

According to analysis, the neuromodulation devices global market is expected to reach $9,427.7 million by 2029 growing at a high single digit CAGR from 2022 to 2029. The factors such as increasing prevalence of chronic pain conditions, central nervous system disorders such as Parkinson disease, Alzheimer disease, Multiple sclerosis, Epilepsy and others (According to U.S. Parkinson’s U.S. foundation, nearly one million people in the U.S. are living with Parkinson's disease (PD) and this number is expected to rise to 1.2 million by 2030. The prevalence of Parkinson’s in the U.K. is a total of about 127,000 people living with the disease, The prevalence of epilepsy is estimated to be 5.0 million people in U.S. in 2022), low approval rate of CNS drugs and favorable reimbursement scenario in major markets are driving the neuromodulation market. The emergence of neuromodulation as add-on therapy, technological innovations in neuromodulation, expansion in emerging markets and the rise in the number of clinical studies performed provides immense opportunities to the neuromodulation market. However, side effects and risks associated with the use, lack of trained professionals, availability of alternative treatments and stringent regulatory guidelines are expected to hamper the market growth.

The neuromodulation global market is segment based on product, application, end - users and geography. Based on the product, the neuromodulation global market is segmented into invasive neuromodulation devices and non-invasive neuromodulation devices. Among these, invasive neuromodulation devices segment accounted for the largest revenue in 2022 and is expected grow at a high single digit CAGR from 2022 to 2029. Invasive neuromodulation segment is further segmented into Spinal Cord Stimulator (SCS), Deep Brain Stimulator (DBS), Sacral Nerve Stimulator (SNS), Vagus Nerve Stimulator (VNS), Hypoglossal Nerve Stimulator (HGNS) and others. Among invasive neuromodulation devices, Spinal cord stimulator (SCS) segment accounted for the largest revenue in 2022 and is expected to grow at a mid single digit CAGR from 2022 to 2029. 

Based on the application, the neuromodulation devices global market is segmented into Pain Management, Central Nervous System, Gastroenterology and Urology, Obstructive Sleep Apnea (OSA) and other. Among applications, pain management segment accounted for the largest revenue in 2022 and is grow at a mid single digit CAGR from 2022 to 2029. 

Pain management is further segmented into chronic pain, failed back surgery syndrome (FBSS) and others. Among pain management, chronic pain segment is the largest and fastest growing segment. Central Nervous System is further segmented into Parkinson’s disease, Dystonia, Epilepsy and others include Obsessive Compulsive Disorder (OCD), Depression, Stroke, and Mood disorders, Anxiety, Central Sleep Apnea and Multiple Sclerosis. Among Central Nervous System disorders, Parkinson’s disease segment accounted for the largest revenue in 2022 and is expected grow at a CAGR mid single digit from 2022 to 2029. Epilepsy segment is the fastest growing segment in 2022 and is expected grow at a double digit CAGR from 2022 to 2029. Gastroenterology and Urology is further segmented into Gastroparesis, Urinary Incontinence and Faecal Incontinence. Among Gastroenterology and Urology, Urinary Incontinence segment accounted for the largest and fastest growing segment.

Based on the end-user, the neuromodulation devices global market is segmented into Hospitals and Ambulatory Surgery Centers, Clinics and Physiotherapy Centers and Others include Home care, Academics and Research Institutes. Among end-user, Hospitals and Ambulatory Surgery Centers is the largest and fastest growing segment and is expected grow at high single digit CAGR from 2022 to 2029.

Based on the region, the neuromodulation devices global market is segmented into North America (U.S. and Rest of North America), Europe (Germany, France, U.K and Rest of Europe), Asia-Pacific (Japan, China, India, and Rest of APAC) and Rest of the world (Brazil, Rest of Latin America and Middle East & others). North America accounted for the largest revenue in 2022 and is expected grow at a high single digit CAGR from 2022 to 2029. The factors such as increasing healthcare expenditure, increasing incidence of chronic pain problems, persistently increasing geriatric population with age related CNS disorders parkinson’s, alzheimer’s, epilepsy and incontinence problems, adoption of neurostimulation devices for the treatment of movement disorders, epilepsy, pain, and depression with rising number of approvals, increasing number of neuromodulation procedures and hospitals, presence of major players, launch of advanced neuromodulation devices by the companies, introduction of remote Neuromodulation Patient-Care Technology to increase the adoption, rising funding for start-up companies for developing unique neuromodulation technologies and presence of dedicated non-profit organization devoted to the advancement of the field of neuromodulation are driving the neuromodulation market in the region.

Asia-Pacific is the fastest growing segment and is expected grow at a double digit CAGR from 2022 to 2029 The factors such as increasing healthcare expenditure, increasing aging population, increasing incidence and prevalence of targeted disease such as Chronic Pain, Parkinson’s disease, Alzheimer’s disease and incontinence problems, increasing adoption of implantable devices, high acceptance of technological advancements, government initiatives to increase awareness by education campaigns and development of neuromodulation devices and their approval in other markets boosts the growth of neuromodulation market in region.

The neuromodulation devices global market is a highly consolidated market hence all the existing players in this market are involved in developing new and advanced technologies to maintain their market shares. Some of the key players in neuromodulation devices global market include Medtronic Plc (Ireland), Abbott Laboratories (U.S.), Boston Scientific Corporation (U.S.), LivaNova Plc (U.K.), Nevro Corporation (U.S.), Inspire Medical Technologies (U.S.), Bioventus (Bioness Inc) (U.S.), Neuropace Inc. (U.S.), Laborie Medical System Inc. (U.S.), Axonics Inc. (U.S.) and others.

Table of Contents


1 Executive Summary
2 Introduction
2.1 Key Takeaways
2.2 Scope of the Report
2.3 Report Description
2.4 Markets Covered
2.5 Stakeholders
2.6 Research Methodology
2.6.1 Market Size Estimation
2.6.2 Market Breakdown and Data Triangulation
2.6.3 Secondary Sources
2.6.4 Primary Sources
2.6.5 Key Data Points from Secondary Sources
2.6.6 Key Data Points from Primary Sources
2.6.7 Assumptions

3 Market Analysis
3.1 Introduction
3.2 Market Segmentation
3.3 Factors Influencing Market
3.3.1 Drivers and Opportunities
3.3.1.1 Growing Prevalence of Treatment Resistant Chronic Pain Conditions
3.3.1.2 Growing Prevalence of Central Nervous System Disorders Such as Parkinson Disease, Alzheimer Disease, Multiple Sclerosis, Epilepsy and Others
3.3.1.3 Low Approval Rate of Cns Drugs
3.3.1.4 Favorable Reimbursement Scenario in Major Markets
3.3.1.5 the Emergence of Neuromodulation as Add-On Therapy
3.3.1.6 Technological Innovations in Neuromodulation
3.3.1.7 Expansion in Emerging Markets
3.3.1.8 the Rise in the Number of Clinical Studies Performed
3.3.2 Restraints and Threats
3.3.2.1 Side Effects and Risks Associated with the Use
3.3.2.2 Lack of Trained Professionals
3.3.2.3 Availability of Alternative Treatments
3.3.2.4 Stringent Regulatory Guidelines
3.4 Regulatory Affairs
3.4.1 International Organization for Standardization
3.4.1.1 Iso 9001: 2015 Quality Management System
3.4.1.2 Iso 13485 Medical Devices
3.4.1.3 Iso 10993 Biological Evaluation of Medical Devices
3.4.2 U.S.
3.4.3 Canada
3.4.4 Europe
3.4.5 Japan
3.4.6 China
3.4.7 India
3.5 Clinical Trials Data
3.6 Technological Advancements
3.6.1 Rechargeable Systems
3.6.2 Focused Ultrasound (Fus)
3.6.3 Miniaturization
3.6.4 Portable Nueromodulation Systems (Pons)
3.6.5 Wearable Neuromodulation Technology
3.6.6 Trans-Spinal Direct Current Stimulation (Tsdcs)
3.6.7 Nano-Neuromodulation
3.6.8 Bioactive Coatings
3.6.9 Transcutaneous Vagus Nerve Stimulation
3.7 Porter's Five Force Analysis
3.7.1 Threat of New Entrants
3.7.2 Threat of Substitutes
3.7.3 Bargaining Power of Suppliers
3.7.4 Bargaining Power of Buyers
3.7.5 Competitive Rivalry
3.8 Supply Chain Analysis
3.9 Reimbursement Scenario
3.9.1 Reimbursement Table
3.10 Funding Scenario
3.11 Market Share Analysis by Major Players
3.11.1 Neuromodulation Devices Global Market Share Analysis
3.11.2 Spinal Cord Stimulators Global Market Share Analysis
3.11.3 Deep Brain Stimulators Global Market Share Analysis
3.11.4 Sacral Nerve Stimulator (Sns) Global Market Share Analysis
3.11.5 Hypoglossal Nerve Stimulator (Hgns) Global Market Share Analysis
3.12 Neuromodulation Devices Number of Units Based on Region
3.12.1 Spinal Cord Stimulation (Scs) Number of Units Based on Region
3.12.2 Deep Brain Stimulation (Dbs) Number of Units Based on Region
3.12.3 Sacral Nerve Stimulation (Sns) Number of Units Based on Region
3.12.4 Vagus Nerve Stimulation (Vns) Number of Units Based on Region
3.12.5 Hypoglossal Nerve Stimulation (Hgns) Number of Units Based on Region
3.13 Market Penetration
3.13.1 United States Obstructive Sleep Apnea Neuromodulation Devices Market Penetration Analysis
3.13.2 United States Drug Resistant Epilepsy Neuromodulation Devices Market Penetration Analysis
3.13.3 United States Depression Neuromodulation Devices Market Penetration Analysis
3.13.4 United States Overactive Bladder Neuromodulation Devices Market Penetration Analysis
3.13.5 United States Chronic Pain Neuromodulation Devices Market Penetration Analysis
3.13.6 Baroreflex Activation Therapy (Bat) Market Penetration, Prevalence, Opportunity and Number of Procedures Performed
3.14 Neuromodulation Devices Company Comparison Table Based on Revenue, Technology, Products and Application

4 Neuromodulation Devices Global Market, Based on Product
4.1 Introduction
4.2 Invasive Neuromodulation Devices
4.2.1 Spinal Cord Stimulation (Scs)
4.2.2 Deep Brain Stimulation (Dbs)
4.2.3 Sacral Nerve Stimulation (Sns)
4.2.4 Vagus Nerve Stimulation (Vns)
4.2.5 Hypoglossal Nerve Stimulation (Hgns)
4.2.6 Other Invasive Neuromodulation Devices
4.2.6.1 Gastric Electric Stimulation (Ges)
4.2.6.2 Respiratory Electrical Stimulation (Res)/Phrenic Nerve Stimulation (Pns)
4.2.6.3 Carotid Sinus Stimulation (Css)
4.2.6.4 Responsive Neurostimulation (Rns)
4.2.6.5 Reactiv8 Technology
4.3 Non-Invasive Neuromodulation Devices
4.3.1 Transcutaneous Electrical Nerve Stimulation (Tens)
4.3.2 Neuromuscular Electrical Stimulation (Nmes)
4.3.3 Other Non-Invasive Neuromodulation Devices
4.3.3.1 Transcranial Magnetic Stimulation (Tms)
4.3.3.2 Portable Neuromodulation Stimulation (Pons)
4.3.3.3 Transcranial Electrical Stimulation (Tes)
4.3.3.4 Transcranial Direct Current Stimulation (Tdcs)
4.3.3.5 Tibial Nerve Stimulation (Tns)
4.3.3.6 Transcranial Alternating Current Stimulation (Tacs)
4.3.3.7 Trigeminal Nerve Stimulation (Tns)
4.3.3.8 Peripheral Nerve Stimulation (Pns)
4.3.3.9 Percutaneous Electrical Nerve Stimulation (Pens)
4.3.3.10 Transcranial Electromagnetic Treatment (Temt)
4.3.3.11 Vestibular Nerve Stimulatio (Vens)
4.3.3.12 Pharyngeal Electrical Stimulation (Pes)
4.3.3.13 Non- Invasive Vagus Nerve Stimulation (N- Vns)
4.3.3.14 Non- Invasive Spinal Cord Stimulation

5 Neuromodulation Devices Global Market, Based on Application
5.1 Introduction
5.2 Pain Management
5.2.1 Chronic Pain
5.2.2 Failed Back Surgery Syndrome (Fbss)
5.2.3 Other Pain Management
5.3 Central Nervous System (Cns)
5.3.1 Parkinson's Disease
5.3.2 Dystonia
5.3.3 Epilepsy
5.3.4 Others
5.4 Gastroenterology and Urology
5.4.1 Gastroparesis
5.4.2 Urinary Incontinence
5.4.3 Faecal Incontinence
5.5 Obstructive Sleep Apnea (Osa)
5.6 Other Applications

6 Neuromodulation Devices Global Market, Based on End-Users
6.1 Introduction
6.2 Hospitals and Ambulatory Surgery Centers (Asc)
6.3 Clinics and Physiotherapy Centers
6.4 Others (Home Care, Academics and Research Institutes)

7 Regional Analysis
7.1 Introduction
7.2 North America
7.2.1 United States (U.S.)
7.2.2 Rest of North America
7.3 Europe
7.3.1 Germany
7.3.2 France
7.3.3 United Kingdom (U.K.)
7.3.4 Rest of Europe
7.4 APAC
7.4.1 Japan
7.4.2 China
7.4.3 India
7.4.4 Rest of APAC
7.5 Rest of the World (Row)
7.5.1 Brazil
7.5.2 Rest of Latin America (Latam)
7.5.3 Middle East and Others

8 Competitive Landscape
8.1 Introduction
8.2 Product Approval
8.3 Product Launch
8.4 Agreement and Collaboration
8.5 Acquisition
8.6 Other Developments

9 Major Companies
9.1 Abbott Laboratories
9.1.1 Overview
9.1.2 Financials
9.1.3 Product Portfolio
9.1.4 Key Developments
9.1.5 Business Strategy
9.1.6 SWOT Analysis
9.2 Axonics Inc.
9.2.1 Overview
9.2.2 Financials
9.2.3 Product Portfolio
9.2.4 Key Developments
9.2.5 Business Strategy
9.2.6 SWOT Analysis
9.3 Bioventus (Bioness Inc)
9.3.1 Overview
9.3.2 Financials
9.3.3 Product Portfolio
9.3.4 Key Developments
9.3.5 Business Strategy
9.3.6 SWOT Analysis
9.4 Boston Scientific Corporation
9.4.1 Overview
9.4.2 Financials
9.4.3 Product Portfolio
9.4.4 Key Developments
9.4.5 Business Strategy
9.4.6 SWOT Analysis
9.5 Inspire Medical System, Inc.
9.5.1 Overview
9.5.2 Financials
9.5.3 Product Portfolio
9.5.4 Key Developments
9.5.5 Business Strategy
9.5.6 SWOT Analysis
9.6 Laborie Medical Technologies, Inc.
9.6.1 Overview
9.6.2 Financials
9.6.3 Product Portfolio
9.6.4 Key Developments
9.6.5 Business Strategy
9.6.6 SWOT Analysis
9.7 Livanova plc
9.7.1 Overview
9.7.2 Financials
9.7.3 Product Portfolio
9.7.4 Key Developments
9.7.5 Business Strategy
9.7.6 SWOT Analysis
9.8 Medtronic plc
9.8.1 Overview
9.8.2 Financials
9.8.3 Product Portfolio
9.8.4 Key Developments
9.8.5 Business Strategy
9.8.6 SWOT Analysis
9.9 Neuropace, Inc.
9.9.1 Overview
9.9.2 Financials
9.9.3 Product Portfolio
9.9.4 Key Developments
9.9.5 Business Strategy
9.9.6 SWOT Analysis
9.10 Nevro Corporation
9.10.1 Overview
9.10.2 Financials
9.10.3 Product Portfolio
9.10.4 Key Developments
9.10.5 Business Strategy
9.10.6 SWOT Analysis

List of Tables
Table 1 Neuromodulation Devices Global Market Revenue, Based on Region, (2021-2029) ($Mn)
Table 2 Scs Number of Units, Based on Region, (2021-2029) (No's)
Table 3 Dbs Number of Units, Based on Region, (2021-2029) (No's)
Table 4 Sns Number of Units, Based on Region, (2021-2029) (No's)
Table 5 Vns Number of Units, Based on Region, (2021-2029) (No's)
Table 6 Hgns Number of Units, Based on Region, (2021-2029) (No's)
Table 7 Neuromodulation Devices Global Market Revenue, Based on Product, (2021-2029) ($Mn)
Table 8 Neuromodulation Devices Global Market Revenue, Based on Region, (2021-2029) ($Mn)
Table 9 Invasive Neuromodulation Devices Global Market Revenue, Based on Product Type, (2021-2029) ($Mn)
Table 10 Invasive Neuromodulation Devices Global Market Revenue, Based on Region, (2021-2029) ($Mn)
Table 11 Spinal Cord Stimulation (Scs) Global Market Revenue, Based on Region, (2021-2029) ($Mn)
Table 12 Deep Brain Stimulation (Dbs) Global Market Revenue, Based on Region, (2021-2029) ($Mn)
Table 13 Sacral Nerve Stimulation (Sns) Global Market Revenue, Based on Region, (2021-2029) ($Mn)
Table 14 Vagus Nerve Stimulation (Vns) Global Market Revenue, Based on Region, (2021-2029) ($Mn)
Table 16 Other Invasive Neuromodulation Devices Global Market Revenue, Based on Region, (2021-2029) ($Mn)
Table 17 Non-Invasive Neuromodulation Devices Global Market Revenue, Based on Product Type, (2021-2029) ($Mn)
Table 18 Non-Invasive Neuromodulation Devices Global Market Revenue, Based on Region, (2021-2029) ($Mn)
Table 19 Transcutaneous Electrical Nerve Stimulation (Tens) Global Market Revenue, Based on Region, (2021-2029) ($Mn)
Table 20 Neuromuscular Electrical Stimulation (Nmes) Global Market Revenue, Based on Region, (2021-2029) ($Mn)
Table 21 Other Non-Invasive Neuromodulation Devices Global Market Revenue, Based on Region, (2021-2029) ($Mn)
Table 22 Neuromodulation Devices Global Market Revenue, Based on Application, (2021-2029) ($Mn)
Table 23 Pain Management Global Market Revenue, Based on Application Type, (2021-2029) ($Mn)
Table 24 Pain Management Global Market Revenue, Based on Region, (2021-2029) ($Mn)
Table 25 Chronic Pain Global Market Revenue, Based on Region, (2021-2029) ($Mn)
Table 26 Failed Back Surgery Syndrome (Fbss) Global Market Revenue, Based on Region, (2021-2029) ($Mn)
Table 27 Other Pain Management Global Market Revenue, Based on Region, (2021-2029) ($Mn)
Table 28 Central Nervous System (Cns) Global Market Revenue, Based on Application Type, (2021-2029) ($Mn)
Table 29 Central Nervous System (Cns) Global Market Revenue, Based on Region, (2021-2029) ($Mn)
Table 30 Parkinson's Disease Global Market Revenue, Based on Region, (2021-2029) ($Mn)
Table 31 Dystonia Global Market Revenue, Based on Region, (2021-2029) ($Mn)
Table 32 Epilepsy Global Market Revenue, Based on Region, (2021-2029) ($Mn)
Table 33 Others Global Market Revenue, Based on Region, (2021-2029) ($Mn)
Table 34 Gastroenterology and Urology Global Market Revenue, Based on Application Type, (2021-2029) ($Mn)
Table 35 Gastroenterology and Urology Global Market Revenue, Based on Region, (2021-2029) ($Mn)
Table 36 Gastroparesis Global Market Revenue, Based on Region, (2021-2029) ($Mn)
Table 37 Urinary Incontinence Global Market Revenue, Based on Region, (2021-2029) ($Mn)
Table 38 Faecal Incontinence Global Market Revenue, Based on Region, (2021-2029) ($Mn)
Table 39 Obstructive Sleep Apnea Global Market Revenue, Based on Region, (2021-2029) ($Mn)
Table 40 Other Applications Global Market Revenue, Based on Region, (2021-2029) ($Mn)
Table 41 Neuromodulation Devices Global Market Revenue, Based on End-Users, (2021-2029) ($Mn)
Table 42 Hospitals and Ambulatory Surgery Centers (Asc) Global Market Revenue, Based on Region, (2021-2029) ($Mn)
Table 43 Clinics and Physiotherapy Centers Global Market Revenue, Based on Region, (2021-2029) ($Mn)
Table 44 Others Global Market Revenue, Based on Region, (2021-2029) ($Mn)
Table 45 Neuromodulation Devices Global Market Revenue, Based on Region, (2021-2029) ($Mn)
Table 46 North America Neuromodulation Devices Market Revenue, Based on Product, (2021-2029) ($Mn)
Table 47 North America Invasive Neuromodulation Devices Market Revenue, Based on Product Type, (2021-2029) ($Mn)
Table 48 North America Non-Invasive Neuromodulation Devices Market Revenue, Based on Product Type, (2021-2029) ($Mn)
Table 49 North America Neuromodulation Devices Market Revenue, Based on Application, (2021-2029) ($Mn)
Table 50 North America Pain Management Market Revenue, Based on Application Type, (2021-2029) ($Mn)
Table 51 North America Central Nervous System Market Revenue, Based on Application Type, (2021-2029) ($Mn)
Table 52 North America Gastroenterology and Urology Market Revenue, Based on Application Type, (2021-2029) ($Mn)
Table 53 North America Neuromodulation Devices Market Revenue, Based on End-Users, (2021-2029) ($Mn)
Table 54 North America Neuromodulation Devices Market Revenue, Based on Country, (2021-2029) ($Mn)
Table 55 United States Neuromodulation Devices Global Market Revenue, Based on Products (2022) ($ Mn)
Table 56 Rest of North America Neuromodulation Devices Global Market Revenue, Based on Products (2022) ($ Mn)
Table 57 Europe Neuromodulation Devices Market Revenue, Based on Product, (2021-2029) ($Mn)
Table 58 Europe Invasive Neuromodulation Devices Market Revenue, Based on Product Type, (2021-2029) ($Mn)
Table 59 Europe Non-Invasive Neuromodulation Devices Market Revenue, Based on Product Type, (2021-2029) ($Mn)
Table 60 Europe Neuromodulation Market Revenue, Based on Application, (2021-2029) ($Mn)
Table 61 Europe Pain Management Market Revenue, Based on Application Type, (2021-2029) ($Mn)
Table 62 Europe Central Nervous System Market Revenue, Based on Application Type, (2021-2029) ($Mn)
Table 63 Europe Gastroenterology and Urology Market Revenue, Based on Application Type, (2021-2029) ($Mn)
Table 64 Europe Neuromodulation Devices Market Revenue, Based on End-Users, (2021-2029) ($Mn)
Table 65 Europe Neuromodulation Devices Market Revenue, Based on Country, (2021-2029) ($Mn)
Table 66 Germany Neuromodulation Devices Global Market Revenue, Based on Products (2022) ($ Mn)
Table 67 France Neuromodulation Devices Global Market Revenue, Based on Products (2022) ($ Mn)
Table 68 United Kingdom Neuromodulation Devices Global Market Revenue, Based on Products (2022) ($ Mn)
Table 69 Rest of Europe Neuromodulation Devices Global Market Revenue, Based on Products (2022) ($ Mn)
Table 70 APAC Neuromodulation Devices Market Revenue, Based on Product, (2021-2029) ($Mn)
Table 71 APAC Invasive Neuromodulation Devices Market Revenue, Based on Product Type, (2021-2029) ($Mn)
Table 72 APAC Non-Invasive Neuromodulation Devices Market Revenue, Based on Product Type, (2021-2029) ($Mn)
Table 73 APAC Neuromodulation Devices Market Revenue, Based on Application, (2021-2029) ($Mn)
Table 74 APAC Pain Management Market Revenue, Based on Application Type, (2021-2029) ($Mn)
Table 75 APAC Central Nervous System Market Revenue, Based on Application Type, (2021-2029) ($Mn)
Table 76 APAC Gastroenterology and Urology Market Revenue, Based on Application Type, (2021-2029) ($Mn)
Table 77 APAC Neuromodulation Devices Market Revenue, Based on End-Users, (2021-2029) ($Mn)
Table 78 APAC Neuromodulation Devices Market Revenue, Based on Country, (2021-2029) ($Mn)
Table 79 Japan Neuromodulation Devices Global Market Revenue, Based on Products (2022) ($ Mn)
Table 80 China Neuromodulation Devices Global Market Revenue, Based on Products (2022) ($ Mn)
Table 81 India Neuromodulation Devices Global Market Revenue, Based on Products (2022) ($ Mn)
Table 82 Rest of APAC Neuromodulation Devices Global Market Revenue, Based on Products (2022) ($ Mn)
Table 83 Row Neuromodulation Devices Market Revenue, Based on Product, (2021-2029) ($Mn)
Table 84 Row Invasive Neuromodulation Devices Market Revenue, Based on Product Type, (2021-2029) ($Mn)
Table 85 Row Non-Invasive Neuromodulation Devices Market Revenue, Based on Product Type, (2021-2029) ($Mn)
Table 86 Row Neuromodulation Market Revenue, Based on Application, (2021-2029) ($Mn)
Table 87 Row Pain Management Market Revenue, Based on Application Type, (2021-2029) ($Mn)
Table 88 Row Central Nervous System Market Revenue, Based on Application Type, (2021-2029) ($Mn)
Table 89 Row Gastroenterology and Urology Marketrevenue, Based on Application Type, (2021-2029) ($Mn)
Table 90 Row Neuromodulation Devices Market Revenue, Based on End-Users, (2021-2029) ($Mn)
Table 91 Row Neuromodulation Devices Market Revenue, Based on Country, (2021-2029) ($Mn)
Table 92 Brazil Neuromodulation Devices Global Market Revenue, Based on Products (2022) ($ Mn)
Table 93 Rest of Latam Neuromodulation Devices Global Market Revenue, Based on Products (2022) ($ Mn)
Table 94 Middle East and Others Neuromodulation Devices Global Market Revenue, Based on Products (2022) ($ Mn)
Table 95 Product Approval (2020-2022)
Table 96 Product Launch (2020-2022)
Table 97 Agreement and Collaboration (2020-2022)
Table 98 Agreement and Collaboration (2020-2022)
Table 99 Other Dvelopments (2020-2022)
Table 100 Abbott Laboratories.: Total Revenue and R&D Expenses, (2020-2022)(Q3) ($Mn)
Table 101 Abbott Laboratories.: Total Revenue, Based on Segment, (2020-2022)(Q3) ($Mn)
Table 102 Abbott Laboratories.: Total Revenue, Based on Sub-Segment, (2020-2022)(Q3) ($Mn)
Table 103 Abbott Laboratories.: Total Revenue, Based on Geography, (2020-2022)(Q3) ($Mn)
Table 104 Axonics Inc.: Total Revenue and R&D Expenses (2020-2022 (Q3) ($Mn)
Table 105 Axonics Inc.: Total Revenue, Based on Segment, (2020-2022 (Q3) ($Mn)
Table 106 Axonics Inc.: Total Revenue, Based on Region, (2020-2022 (Q3) ($Mn)
Table 107 Bioventus.: Total Revenue and R&D Expenses (2020-2022 (Q3) ($Mn)
Table 108 Bioventus.: Total Revenue, Based on Segment, (2020-2022 (Q3) ($Mn)
Table 109 Bioventus.: Total Revenue, Based on Region, (2020-2022 (Q3) ($Mn)
Table 110 Boston Scientific Corporation : Total Revenue and R&D Expenses, (2020-2022 (Q3) ($Mn)
Table 111 Boston Scientific Corporation: Total Revenue, Based on Segment, (2020-2022 (Q3) ($Mn)
Table 112 Boston Scientific Corporation: Total Revenue, Based on Med Surg Sub - Segment, (2020-2022 (Q3) ($Mn)
Table 113 Boston Scientific Corporation: Total Revenue, Based on Geography, (2020-202 (Q3) ($Mn)
Table 114 Inspire Medical System, Inc.: Total Revenue and R&D Expenses, (2020-2022 (Q3) ($Mn)
Table 115 Inspire Medical System,Inc.: Total Revenue, Based on Geography, (2020-2022) (Q3) ($Mn)
Table 116 Livanova plc.: Total Revenue and R&D Expenses, (2020-2022 (Q3) ($Mn)
Table 117 Livanova plc.: Total Revenue, Based on Segment, (2020-2022 (Q3) ($Mn)
Table 118 Livanova plc.: Total Revenue, Based on Geography, (2020-2022 (Q3) ($Mn)
Table 119 Medtronic, plc: Total Revenue and R&D Expenses, (2020-2022)(Q2) ($Mn)
Table 120 Medtronic, plc: Total Revenue, Based on Segments, (2020-2022)(Q2) ($Mn)
Table 121 Medtronic, plc: Neuromodulation Total Revenue, Based on Sub-Segments, (2022-2022)(Q2) ($Mn)
Table 122 Medtronic, plc: Total Revenue, Based on Geography, (2021-2023)(Q2) ($Mn)
Table 123 Neuropace, Inc.: Total Revenue and R&D Expenses, (2020-2022 (Q3) ($Mn)
Table 124 Nevro Corporation : Total Revenue and R&D Expenses (2020-2022 (Q3) ($Mn)
Table 125 Nevro Corporation: Total Revenue, Based on Geography, (2020-2022 (Q3) ($Mn)

List of Figures
Figure 1 Neuromodulation Devices Global Market Revenue, Based on Region (2021-2029) ($Mn)
Figure 2 Research Methodology: Neuromodulation Devices Global Market
Figure 3 Neuromodulation Devices Global Market: Top-Down and Bottom-Up Approach
Figure 4 Neuromodulation Devices Global Market: Forecasting Model
Figure 5 Neuromodulation Devices Global Market: Market Breakdown and Data Triangulation
Figure 6 Neuromodulation Devices Global Market Segmentation
Figure 7 Market Dynamics
Figure 8 Neuromodulation Devices Clinical Trial Analysis
Figure 9 Neuromodulation Devices Clinical Trial Analysis
Figure 10 Neuromodulation Devices Clinical Trial Analysis
Figure 11 Neuromodulation Devices Global Market: Porter's Analysis
Figure 12 Neuromodulation Devices: Supply Chain Analysis
Figure 13 Neuromodulation Devices Global Market Share Analysis, Based on Key Players, 2022 (%)
Figure 14 Spinal Cord Stimulator (Scs) Global Market Share Analysis, Based on Key Players, 2022 (%)
Figure 15 Deep Brain Stimulator (Dbs) Global Market Share Analysis, Based on Key Players, 2022 (%)
Figure 16 Sacral Nerve Stimulator (Sns) Global Market Share Analysis, Based on Key Players, 2022 (%)
Figure 17 Hypoglossal Nerve Stimulator (Hgns) Global Market Share Analysis, Based on Key Players, 2022 (%)
Figure 18 United States Obstructive Sleep Apnea Neuromodulation Devices Market Penetration, 2022 (%)
Figure 19 United States Drug Resistant Epilepsy Neuromodulation Devices Market Penetration, 2022 (%)
Figure 20 United States Depression Neuromodulation Devices Market Penetration, 2022 (%)
Figure 21 United States Overactive Bladder Neuromodulation Devices Market Penetration, 2022 (%)
Figure 22 United States Chronic Pain Neuromodulation Devices Market Penetration, 2022 (%)
Figure 23 U.S. Bat Market Penetration, Opportunity and Number of Procedures Performed, (2022)
Figure 24 E.U. Countries Bat Market Penetration, Opportunity and Number of Procedures Performed, (2022)
Figure 25 5 APAC Countries Bat Market Penetration, and Opportunity, (2022)
Figure 26 Neuromodulation Devices Global Market Share, Based on Product (2022 V/S 2029) (%)
Figure 27 Invasive Neuromodulation Devices Global Market Share, Based on Product Type (2022 V/S 2029) (%)
Figure 28 Spinal Cord Stimulation (Scs) Global Market Revenue, Based on Country (2022) ($ Mn)
Figure 29 Deep Brain Stimulation (Dbs) Global Market Revenue, Based on Country (2022) ($ Mn)
Figure 30 Sacral Nerve Stimulation (Sns) Global Market Revenue, Based on Country (2022) ($ Mn)
Figure 31 Vagus Nerve Stimulation (Vns) Global Market Revenue, Based on Country (2022) ($ Mn)
Figure 32 Hypoglossal Nerve Stimulation (Hgns) Global Market Revenue, Based on Country (2022) ($ Mn)
Figure 33 Other Invasive Neuromodulation Global Market Revenue, Based on Country (2022) ($ Mn)
Figure 34 Non-Invasive Neuromodulation Devices Global Market Share, Based on Product Type, (2022 V/S 2029) (%)
Figure 35 Transcutaneous Electrical Nerve Stimulation (Tens) Global Market Revenue, Based on Country (2022) ($ Mn)
Figure 36 Neuromuscular Electrical Stimulation (Nmes) Global Market Revenue, Based on Country (2022) ($ Mn)
Figure 37 Other Non-Invasive Neuromodulation Devices Global Market Revenue, Based on Country (2022) ($ Mn)
Figure 38 Neuromodulation Devices Global Market Share, Based on Application (2022 V/S 2029) (%)
Figure 39 Pain Management Global Market Share, Based on Application Type (2022 V/S 2029) (%)
Figure 40 Central Nervous System (Cns) Global Market Share, Based on Application Type, (2022 V/S 2029) (%)
Figure 41 Gastroenterology and Urology Global Market Share, Based on Application Type, (2022 V/S 2029) (%)
Figure 42 Neuromodulation Devices Global Market Share, Based on End-Users (2022 V/S 2029) (%)
Figure 43 Neuromodulation Devices Global Market Revenue, Based on Region (2021-2029) ($Mn), CAGR (%)
Figure 44 Neuromodulation Devices Global Market Share, Based on Geography (2022) (%), Country ($Mn)
Figure 45 North America Neuromodulation Devices Market Share, Based on Products, (2022 V/S 2029) (%)
Figure 46 North America Invasive Neuromodulation Devices Market Share, Based on Product Type (2022 V/S 2029) (%)
Figure 47 North America Non-Invasive Neuromodulation Devices Market Share, Based on Product Type (2022 V/S 2029) (%)
Figure 48 North America Neuromodulation Devices Market Share, Based on Application (2022 V/S 2029) (%)
Figure 49 North America Pain Management Market Share, Based on Application Type (2022 V/S 2029) (%)
Figure 50 North America Central Nervous System Market Share, Based on Application Type (2022 V/S 2029) (%)
Figure 51 North America Gastroenterology/Urology Market Share, Based on Application Type (2022 V/S 2029) (%)
Figure 52 North America Neuromodulation Devices Market Share, Based on End-user (2022 V/S 2029) (%)
Figure 53 North America Neuromodulation Devices Market, Based on Country (2022 V/S 2029) (%)
Figure 54 U.S. Neuromodulation Devices Market Revenue, Based on Products and Applications (2022 V/S 2029) ($Mn)
Figure 55 U.S. Neuromodulation Devices Market Revenue, Based on End-users (2022 V/S 2029) ($Mn)
Figure 56 Rest of North America Neuromodulation Devices Market Revenue, Based on Products and Applications (2022 V/S 2029) ($Mn)
Figure 57 Rest of North America Neuromodulation Devices Market Revenue, Based on End-users (2022 V/S 2029) ($Mn)
Figure 58 Europe Neuromodulation Devices Market Share, Based on Product, (2022 V/S 2029) (%)
Figure 59 Europe Invasive Neuromodulation Devices Market Share, Based on Product Type (2022 V/S 2029) (%)
Figure 60 Europe Non-Invasive Neuromodulation Devices Market Share, Based on Product Type (2022 V/S 2029) (%)
Figure 61 Europe Neuromodulation Devices Market Share, Based on Application (2022 V/S 2029) (%)
Figure 62 Europe Pain Management Market Revenue, Based on Application Type (2022 V/S 2029) (%)
Figure 63 Europe Central Nervous System Market Share, Based on Application Type (2022 V/S 2029) (%)
Figure 64 Europe Gastroenterology/Urology Market Share, Based on Application Type (2022 V/S 2029) (%)
Figure 65 Europe Neuromodulation Devices Market Share, Based on End-users (2022 V/S 2029) (%)
Figure 66 Europe Neuromodulation Devices Market Share, Based on Country (2022 V/S 2029) (%)
Figure 67 Germany Neuromodulation Devices Market Revenue, Based on Products and Applications (2022 V/S 2029) ($Mn)
Figure 68 Germany Neuromodulation Devices Market Revenue, Based on End-Users (2022 V/S 2029) ($Mn)
Figure 69 France Neuromodulation Devices Market Revenue, Based on Products and Applications (2022 V/S 2029) ($Mn)
Figure 70 France Neuromodulation Devices Market Revenue, Based on End-users (2022 V/S 2029) ($Mn)
Figure 71 U.K. Neuromodulation Devices Market Revenue, Based on Products and Applications (2022 V/S 2029)($Mn)
Figure 72 U.K. Neuromodulation Devices Market Revenue, Based on End-users (2022 V/S 2029) ($Mn)
Figure 73 Rest of Europe Neuromodulation Devices Market Revenue,Based on Product and Application (2022 V/S 2029) ($Mn)
Figure 74 Rest of Europe Neuromodulation Devices Market Revenue, Based on End-user (2022 V/S 2029) (%)
Figure 75 APAC Neuromodulation Devices Market Share, Based on Product, (2022 V/S 2029) (%)
Figure 76 APAC Invasive Neuromodulation Devices Market Share, Based on Product Type (2022 V/S 2029) (%)
Figure 77 APAC Non-Invasive Neuromodulation Devices Market Share, Based on Product Type (2022 V/S 2029) (%)
Figure 78 APAC Neuromodulation Devices Market Share, Based on Application (2022 V/S 2029) (%)
Figure 79 APAC Pain Management Market Share, Based on Application Type (2022 V/S 2029) (%)
Figure 80 APAC Central Nervous System Market Share, Based on Application Type (2022 V/S 2029) (%)
Figure 81 APAC Gastroenterology/Urology Market Share, Based on Application Type (2022 V/S 2029) (%)
Figure 82 APAC Gastroenterology/Urology Market Share, Based on End-users (2022 V/S 2029) (%)
Figure 83 APAC Neuromodulation Devices Market Share, Based on Country (2022 V/S 2029) (%)
Figure 84 Japan Neuromodulation Devices Market Revenue, Based on Product and Application (2022 V/S 2029) ($Mn)
Figure 85 Japan Neuromodulation Devices Market Revenue, Based on End-user (2022 V/S 2029) ($Mn)
Figure 86 China Neuromodulation Devices Market Revenue, Based on Products and Applications (2022 V/S 2029) ($Mn)
Figure 87 China Neuromodulation Devices Market Revenue, Based on End-users (2022 V/S 2029) ($Mn)
Figure 88 India Neuromodulation Devices Market Revenue, Based on Products and Applications (2022 V/S 2029) ($Mn)
Figure 89 India Neuromodulation Devices Market Revenue, Based on End-users (2022 V/S 2029) ($Mn)
Figure 90 Rest of APAC Neuromodulation Devices Market Revenue, Based on Product and Application (2022 V/S 2029) ($Mn)
Figure 91 Rest of APAC Neuromodulation Devices Market Revenue, Based on End-user (2022 V/S 2029) ($Mn)
Figure 92 Row Neuromodulation Devices Market Share, Based on Product (2022 V/S 2029) (%)
Figure 93 Row Invasive Neuromodulation Devices Market Share, Based on Product Type (2022 V/S 2029) (%)
Figure 94 Row Non-Invasive Neuromodulation Devices Market Share, Based on Product Type (2022 V/S 2029) (%)
Figure 95 Row Neuromodulation Devices Market Share, Based on Application (2022 V/S 2029) (%)
Figure 96 Row Pain Management Market Share, Based on Application Type (2022 V/S 2029) (%)
Figure 97 Row Central Nervous System Market Share, Based on Application Type (2022 V/S 2029) (%)
Figure 98 Row Gastroenterology/Urology Market Share, Based on Application Type (2022 V/S 2029) (%)
Figure 99 Row Neuromodulation Devices Market Share, Based on End-user (2022 V/S 2029) (%)
Figure 100 Row Neuromodulation Devices Market Share, Based on Country (2022 V/S 2029) (%)
Figure 101 Brazil Neuromodulation Devices Market Revenue, Based on Products and Applications (2022 V/S 2029) ($Mn)
Figure 102 Brazil Neuromodulation Devices Market Revenue, Based on End-users (2022 V/S 2029) ($Mn)
Figure 103 Rest of Latam Neuromodulation Devices Market Revenue, Based on Product and Application (2022 V/S 2029) ($Mn)
Figure 104 Rest of Latam Neuromodulation Devices Market Revenue, Based on End-user (2022 V/S 2029) ($Mn)
Figure 105 Middle East and Others Neuromodulation Devices Market Revenue, Based on Product and Application (2022 V/S 2029) ($Mn)
Figure 106 Middle East and Others Neuromodulation Devices Market Revenue, Based on End-user (2022 V/S 2029) ($Mn)
Figure 107 Key Growth Strategies, (2020-2022)
Figure 108 SWOT: Abbott Laboratories
Figure 109 SWOT: Axonics Inc.
Figure 110 SWOT: BioventUS
Figure 111 SWOT: Boston Scientific Corporation
Figure 112 SWOT: Inspire Medical System, Inc.
Figure 113 SWOT: Laborie Medical Technology Inc.
Figure 114 SWOT: Livanova plc
Figure 115 SWOT: Medtronic plc.
Figure 116 SWOT: Neuropace, Inc.
Figure 117 SWOT: Nevro Corporation

Samples

Loading
LOADING...

Companies Mentioned

  • Abbott Laboratories
  • Atrotech Oy
  • Avery Biomedical Devices Inc.
  • AxioBionics
  • Axonics Inc.
  • Beijing Pins Medical Co., Ltd.
  • Beurer GMBH
  • Bioventus Inc (Bioness, Inc.)
  • BioWave Corporation
  • Bluewind Medical
  • Boston Scientific
  • Brainsway
  • Cala Health
  • Cefaly Technology
  • CVRx, Inc.
  • Cymedica Orthopedics
  • DyAnsys
  • EB Neuro S.P.A.
  • electroCore
  • eNeura Inc
  • Fysiomed B.V.
  • Gimer Medical
  • Inspire Medical Systems, Inc
  • Laborie Medical System Inc
  • Livanova Plc
  • Magnus Medical
  • Magstim TMS
  • Magventure A/S
  • Mainstay Medical
  • Medtronic Plc
  • NeurAxis
  • Neurocare Group Gmbh
  • Neuroelectrics
  • Neurolief Ltd
  • NeuroMetrix
  • Neuronetics
  • Neuropace Inc
  • Neurosigma Inc.
  • Neurovalens
  • Nevro Corporation
  • Nexstim Plc
  • Nyxoah SA
  • Phagenesis
  • Precisis AG

Related Topics

Related Reports

Neuromodulation - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029 - Product Image

Neuromodulation - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

  • Report
  • 115 Pages
  • Global
From
Neuromodulation Devices Market Report 2024-2034 - Product Image

Neuromodulation Devices Market Report 2024-2034

  • Report
  • 251 Pages
  • Global
From
Global Neuromodulation Market by Type (Internal (Spinal Cord Stimulation, Deep Brain Stimulation), External (Transcranial Magnetic Stimulation), Application (Tremor, Epilepsy, Parkinson's Disease, Depression, Gastroparesis), and Region - Forecast to 2028 - Product Image

Global Neuromodulation Market by Type (Internal (Spinal Cord Stimulation, Deep Brain Stimulation), External (Transcranial Magnetic Stimulation), Application (Tremor, Epilepsy, Parkinson's Disease, Depression, Gastroparesis), and Region - Forecast to 2028

  • Report
  • 204 Pages
  • Global
From
Neuromodulation Global Market Report 2024 - Product Image

Neuromodulation Global Market Report 2024

  • Report
  • 200 Pages
  • Global
From
Global Neuromodulation Devices Market Report and Forecast 2023-2031 - Product Image

Global Neuromodulation Devices Market Report and Forecast 2023-2031

  • Report
  • 140 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.